Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly
Status:
Completed
Trial end date:
2017-02-16
Target enrollment:
Participant gender:
Summary
The purpose is to compare the efficacy and safety of lanreotide autogel® 60mg, 90mg or 120mg
with lanreotide 40mg PR in subjects with active acromegaly.